Solid Biosciences IncSLDB
Price$6.98

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$207.1MTTM through 30 Jun 2026
Free Cash Flow -$187.8MTTM through 30 Jun 2026

Margins

Current

Returns

-55.4%ROE
-49.2%ROA

Balance Sheet Health

Current Ratio13.82x
Cash & Equivalents$159.4M

Quality Metrics

Altman Z-Score8.16
Piotroski F-Score2 / 9
Earnings-Beat Rate33.3%

Multi-Year Trend

Revenue
'16'17'18'19'20'21'22
FY2022: $8.1M

Dividend

No dividend

Capital Allocation

R&D Spend$167.4M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.